Tumor Markers for Ovarian vs Uterine Mass Evaluation
For ovarian masses, measure CA-125 as the primary tumor marker, supplemented by CA 19-9, CEA, AFP, beta-hCG, and inhibin based on clinical context; for uterine (endometrial) masses, CA-125 is the most useful marker despite limited sensitivity and specificity. 1
Ovarian Mass Evaluation
Primary Markers
CA-125 is the cornerstone tumor marker for suspected ovarian malignancy, with 80% sensitivity in stage II or greater disease, though only 50% sensitivity in stage I 2. The marker's utility is highest in postmenopausal women, where false-positive rates from benign conditions (endometriosis, fibroids, pregnancy, pelvic inflammatory disease) are substantially lower 2.
Supplementary Markers Based on Clinical Context
The NCCN guidelines 1 recommend measuring additional markers when clinically indicated:
CA 19-9 and CEA: Particularly valuable for mucinous histology. A high CA-125/CEA ratio optimizes specificity for ovarian versus gastrointestinal primary tumors 2. CA 19-9 offers high sensitivity for mucinous histotypes that often fail to express CA-125 3.
AFP (alpha-fetoprotein): Essential in women younger than 35 years with a pelvic mass to assess for germ cell tumors 1
Beta-hCG: Measured to rule out pregnancy and assess for germ cell tumors 1
Inhibin: Useful for granulosa cell tumors (sex cord-stromal tumors) 1, 3
Important Caveats for Ovarian Markers
The NCCN panel explicitly does not recommend HE4 and CA-125 combined with ROMA algorithm for determining the status of an undiagnosed pelvic mass, despite FDA approval for risk estimation 1. This represents a critical divergence between regulatory approval and expert consensus.
For mucinous histology specifically, gastrointestinal tract evaluation is mandatory to distinguish primary ovarian mucinous carcinoma from metastases to the ovary 1.
Uterine (Endometrial) Mass Evaluation
Primary Marker
CA-125 is the most commonly used tumor marker for endometrial carcinoma, though its clinical utility is limited 3, 4, 5. Preoperative CA-125 levels correlate with:
- Stage
- Depth of myometrial invasion
- Histologic grade
- Cervical invasion
- Peritoneal cytology
- Lymph node status
- Clinical outcome 3
Critical Limitations
There are currently no tumor markers for endometrial cancer that exhibit both high sensitivity and specificity 4. CA-125 is elevated in only 57% of endometrial carcinoma cases when combined with SCC and CEA 6. This stands in stark contrast to ovarian cancer, where marker utility is substantially higher.
Serial CA-125 measurements can serve as an indicator of disease activity and are useful for post-treatment surveillance, but should not be relied upon for initial diagnosis 3.
Practical Algorithm for Differential Diagnosis
When facing an indeterminate pelvic mass where the organ of origin is uncertain:
- Order CA-125 universally as the first-line tumor marker
- Add CA 19-9 and CEA to calculate the CA-125/CEA ratio for distinguishing ovarian from gastrointestinal primaries 2
- In women <35 years, add AFP and beta-hCG to exclude germ cell tumors 1
- If solid components or sex cord-stromal tumor suspected, add inhibin 1
- Imaging (MRI with contrast) is superior to tumor markers alone for determining organ of origin when ultrasound is indeterminate 7
Common Pitfalls to Avoid
- Do not use CA-125 alone for screening in average-risk women—it lacks sufficient positive predictive value 2, 8
- Do not interpret elevated CA-125 in isolation in premenopausal women—false positives from benign conditions are common 2
- Do not rely on tumor markers to definitively distinguish uterine from ovarian origin—imaging (particularly MRI) and WT-1 immunohistochemistry on tissue are more reliable 9
- Do not use HE4/ROMA for initial pelvic mass evaluation despite FDA approval—NCCN guidelines do not support this approach 1